Tags

Type your tag names separated by a space and hit enter

[Brexpiprazole for treatment of schizophrenia: a critical literature study].
Tijdschr Psychiatr. 2021; 63(1):48-55.TP

Abstract

Background Brexpiprazole has been registered in the Netherlands and Belgium for the treatment of schizophrenia since 2019. It is a third-generation antipsychotic drug with a number of pharmacological similarities to aripiprazole and cariprazine. Aim To critically evaluate the pharmacology, effectiveness and side effects of brexpiprazole in the treatment of schizophrenia using the hitherto available double-blind, placebo-controlled study. Method A clinically oriented study of the literature. Results Brexpiprazole is effective in the treatment of schizophrenia and has few extrapyramidal side effects, metabolic side effects and moderate weight gain, no QTc prolongation, no sedation, and little influence on blood prolactin levels. Limited dose titration is required when initiated on brexpiprazole. Conclusion Brexpiprazole is a treatment option for schizophrenia, with a relatively favorable side effect profile. The position of brexpiprazole within the current treatment algorithm should become clear through future research and clinical experience. Tijdschrift voor Psychiatrie 63(2021)1, 48-55.

Authors

Spoelstra SK
No affiliation info available
Baas CAJ
No affiliation info available
Knegtering H
No affiliation info available

MeSH

Antipsychotic AgentsBelgiumHumansNetherlandsQuinolonesRandomized Controlled Trials as TopicSchizophreniaThiophenesTreatment Outcome

Pub Type(s)

Journal Article

Language

dut

PubMed ID

33537974

Citation

Spoelstra, S K., et al. "[Brexpiprazole for Treatment of Schizophrenia: a Critical Literature Study]." Tijdschrift Voor Psychiatrie, vol. 63, no. 1, 2021, pp. 48-55.
Spoelstra SK, Baas CAJ, Knegtering H. [Brexpiprazole for treatment of schizophrenia: a critical literature study]. Tijdschr Psychiatr. 2021;63(1):48-55.
Spoelstra, S. K., Baas, C. A. J., & Knegtering, H. (2021). [Brexpiprazole for treatment of schizophrenia: a critical literature study]. Tijdschrift Voor Psychiatrie, 63(1), 48-55.
Spoelstra SK, Baas CAJ, Knegtering H. [Brexpiprazole for Treatment of Schizophrenia: a Critical Literature Study]. Tijdschr Psychiatr. 2021;63(1):48-55. PubMed PMID: 33537974.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Brexpiprazole for treatment of schizophrenia: a critical literature study]. AU - Spoelstra,S K, AU - Baas,C A J, AU - Knegtering,H, PY - 2021/2/4/entrez PY - 2021/2/5/pubmed PY - 2021/6/16/medline SP - 48 EP - 55 JF - Tijdschrift voor psychiatrie JO - Tijdschr Psychiatr VL - 63 IS - 1 N2 - Background Brexpiprazole has been registered in the Netherlands and Belgium for the treatment of schizophrenia since 2019. It is a third-generation antipsychotic drug with a number of pharmacological similarities to aripiprazole and cariprazine. Aim To critically evaluate the pharmacology, effectiveness and side effects of brexpiprazole in the treatment of schizophrenia using the hitherto available double-blind, placebo-controlled study. Method A clinically oriented study of the literature. Results Brexpiprazole is effective in the treatment of schizophrenia and has few extrapyramidal side effects, metabolic side effects and moderate weight gain, no QTc prolongation, no sedation, and little influence on blood prolactin levels. Limited dose titration is required when initiated on brexpiprazole. Conclusion Brexpiprazole is a treatment option for schizophrenia, with a relatively favorable side effect profile. The position of brexpiprazole within the current treatment algorithm should become clear through future research and clinical experience. Tijdschrift voor Psychiatrie 63(2021)1, 48-55. SN - 0303-7339 UR - https://www.unboundmedicine.com/medline/citation/33537974/[Brexpiprazole_for_treatment_of_schizophrenia:_a_critical_literature_study]_ DB - PRIME DP - Unbound Medicine ER -